Phase I/II Study of Intrathecal/Ommaya T-DXd in HER2-Expressing Breast Cancer With Leptomeningeal/Brain Metastases
A legfontosabb adatok
- Ki végzi
- Fudan University
- Hol
- Kína2 helyszín, 1 országbanVálassz országot a helyszínekhez
- Azonosító
- Állapot
- Toboroz
- Fázis
- 1/2. fázis
- Résztvevők
- 139 fő, tervezett
- Kezdés
- 2025. máj. 12.
- Várható befejezés
- 2027. jún. 28.
- A vizsgálat típusa
- Beavatkozással járó, 10 csoport
- A vizsgált kezelések
- T-DXd
- A regiszteradat frissítve
- 2026. október 26.
Ki vehet részt
The trial is looking for adults with HER2-expressing advanced or spread breast cancer that has reached the brain lining (leptomeningeal metastasis) and/or the brain. T-DXd is given into the spinal fluid together with treatment through the blood.
- Életkor
- 18 years and older
- Nem
- All sexes
- A betegség stádiuma
- Advanced or metastatic breast cancer with leptomeningeal metastasis. People with active brain metastases only need at least one brain tumour that can be measured on scans (RANO-BM criteria). Some groups need cancer in the brain or brain lining that is growing.
- Korábbi kezelés
- No radiotherapy, chemotherapy, targeted therapy, immunotherapy, endocrine therapy or surgery within 2 weeks before joining (or within 5 half-lives of the earlier therapy, whichever is shorter). Side effects of earlier treatment must have eased to Grade 1 or lower. Some groups are for people who already had T-DXd, others for people who never had it.
- Biomarker vagy leletérték
- HER2-expressing breast cancer: HER2-positive or HER2-low (IHC 1+ or 2+/ISH-), depending on the group.
- A részvétel fő kizáró okai
- Another cancer in the past 5 years, except some early or skin cancers that were treated and gone
- Past lung inflammation (ILD/pneumonitis) needing steroids, or current or suspected ILD/pneumonitis
- Known HIV infection, active hepatitis B or C, or uncontrolled infections needing IV medicines
- Active autoimmune disease, or immunosuppressants or systemic steroids over 10 mg/day prednisone equivalent within 2 weeks
- Pregnant or breastfeeding women, or people unwilling or unable to use effective birth control
A regiszter összes feltétele (18)A regiszter feltételeinek elrejtése
Ki vehet részt
- Age ≥18 years, regardless of gender
- HER2-expressing advanced or metastatic breast cancer
- Leptomeningeal metastasis
- Subjects with active brain metastases only must have at least one intracranially measurable lesion (RANO-BM criteria)
- Adequate organ and bone marrow function
- No radiotherapy, chemotherapy, targeted therapy, immunotherapy, endocrine therapy, or surgery within 2 weeks prior to enrollment (or within 5 half-lives of prior therapy, whichever is shorter)
- All prior treatment-related toxicities must have resolved to ≤Grade 1
Ki nem vehet részt
- Uncontrolled concurrent illnesses including, but not limited to: persistent or active infections, uncontrolled or clinically significant cardiovascular diseases, severe chronic gastrointestinal disorders with diarrhea, or psychiatric/social conditions that may compromise compliance with study requirements, significantly increase AE risks, or impair the subject's ability to provide written informed consent
- Use of immunosuppressants or systemic corticosteroids (>10 mg/day prednisone equivalent) for immunosuppression within 2 weeks prior to first dose (excluding intranasal/inhaled corticosteroids)
- Diagnosis of other malignancies within the past 5 years, except for cured carcinoma in situ of the cervix, basal cell carcinoma or squamous cell carcinoma of the skin, other in situ carcinomas, or papillary thyroid carcinoma
- History of (non-infectious) ILD/non-infectious pneumonitis requiring steroid therapy, current ILD/non-infectious pneumonitis, or suspected ILD/non-infectious pneumonitis that cannot be ruled out by imaging during screening
- Any active autoimmune disease or history of autoimmune disease with potential recurrence
- Uncontrolled infections requiring IV antibiotics, antivirals, or antifungals
- Active primary immunodeficiency, known HIV infection, active HBV (HBsAg+ with HBV DNA ≥500 IU/mL) or HCV infection. HCV antibody-positive subjects are eligible only if PCR confirms HCV RNA negativity
- Radiographic evidence of tumor encasement/invasion of major blood vessels, or investigator-determined high risk of fatal hemorrhage due to probable vascular invasion during treatment
- Any other condition deemed by investigators to potentially affect trial conduct or outcome interpretation
- Clinically significant pulmonary comorbidities
- Pregnant/lactating women, or subjects of reproductive potential unwilling/unable to use effective contraception
Alkalmassági kérdőív
Ez nem döntés: hogy ki vehet részt, azt csak a vizsgálat csapata mondhatja meg.
- Életkor
- Breast cancer
Ez a vizsgálat jelenleg itt érhető el: Kína.
Egy országban van helyszíne. Válassz országot, hogy lásd a helyszíneket.
A vizsgálatról
Mit akar kideríteni a vizsgálat
Multiple trials confirm systemic T-DXd efficacy in HER2+ breast cancer with leptomeningeal/brain metastases, yet median LM survival remains 3-4 months, highlighting unmet needs. While systemic therapies improve survival, intracranial disease control remains limited due to poor BBB penetration. Preclinical data show no detectable T-DXd/DXd in CSF, though intrathecal trastuzumab demonstrates preliminary safety/efficacy in HER2+ LM.
A teljes eredeti leírásKevesebb
This study evaluates intrathecal/intra-Ommaya T-DXd plus systemic therapy in active HER2+ meningeal/brain metastases, assessing safety, intracranial efficacy, and CSF/peripheral blood T-DXd distribution to clarify BBB penetration potential. Findings may guide novel therapeutic strategies for this high-need population.
A vizsgálat 10 csoportja
- Phase I/Arm A(Intrathecal Dose-Escalation Phase)A vizsgált kezelés
Population : T-DXd-naïve subjects with leptomeningeal metastases (LM), with or without concurrent brain metastases (BM). Cycle 1 : Intrathecal (IT) T-DXd monotherapy to assess cerebrospinal fluid (CSF) and systemic pharmacokinetics (PK). Cycles 2+ : IT T-DXd combined with intravenous (IV) T-DXd in a dose-escalation design to determine the maximum tolerated dose (MTD) . DLT Evaluation : The first two cycles serve as the dose-limiting toxicity (DLT) observation window . Endpoint : The recommended Phase 2 dose (RP2D) will be determined by investigator assessment
Kezelés: T-DXd
- Phase I/Arm B(Systemic-to-Intrathecal Transition Phase)A vizsgált kezelés
Population : T-DXd-naïve subjects with LM ± BM. Cycle 1 : IV T-DXd monotherapy to characterize CSF and systemic PK profiles. Cycles 2+ : IT administration of the RP2D of T-DXd combined with IV therapy
Kezelés: T-DXd
- Phase II/Arm AA vizsgált kezelés
HER2-positive advanced breast cancer with progressive leptomeningeal and/or brain metastases after prior T-DXd therapy
Kezelés: T-DXd
- Phase II/Arm BA vizsgált kezelés
HER2-low (IHC 1+ or 2+/ISH-) advanced breast cancer with progressive leptomeningeal and/or brain metastases after prior T-DXd therapy
Kezelés: T-DXd
- Phase II/Arm CA vizsgált kezelés
HER2-positive advanced breast cancer with progressive brain metastases (without leptomeningeal involvement) after prior T-DXd therapy
Kezelés: T-DXd
- Phase II/Arm DA vizsgált kezelés
HER2-low advanced breast cancer with progressive brain metastases (without leptomeningeal involvement) after prior T-DXd therapy
Kezelés: T-DXd
- Phase II/Arm EA vizsgált kezelés
T-DXd-naïve HER2-positive advanced breast cancer with progressive leptomeningeal and/or brain metastases
Kezelés: T-DXd
- Phase II/Arm FA vizsgált kezelés
T-DXd-naïve HER2-low advanced breast cancer with progressive leptomeningeal and/or brain metastases
Kezelés: T-DXd
- Phase II/Arm GA vizsgált kezelés
T-DXd-naïve HER2-positive advanced breast cancer with progressive brain metastases (without leptomeningeal involvement)
Kezelés: T-DXd
- Phase II/Arm HA vizsgált kezelés
T-DXd-naïve HER2-low advanced breast cancer with progressive brain metastases (without leptomeningeal involvement)
Kezelés: T-DXd
Következő lépések
Az orvosodnak
Kérdőlap az orvosnak
PDF az orvosodnak: mit vizsgál a vizsgálat, ki vehet részt, és 2 kérdés a részvételi feltételekről, hellyel a válaszoknak és a jegyzeteknek.
PDF, US Letter, 1–2 oldal. A4 méretben
A vizsgálati csapatnak
Kérdések a vizsgálat csapatának
- Milyen gyakran kell bejárnom, és egy-egy alkalom mennyi ideig tart?
- Megtérítik az utazási költséget?
- Megtarthatom a saját orvosomat?
- Mi történik, ha ki akarok lépni?
Contact the study team: see the registry record → Contacts and Locations
Adatok és források
- Regiszteradat
- Szerepel a ClinicalTrials.gov-on.
- Hivatalos cím
- Evaluating Safety and Efficacy of INtrathecal or Ommaya ReserVoir Administration of T-DXd in Patients With HER2-Expressing Breast Cancer With Active Leptomeningeal and/or Brain Metastases Based on Systemic Therapy: Phase I/II Study
- MI-összefoglaló
- A vizsgálat saját részvételi feltételeiből. Gépi kiolvasás: 2026. november 15.
- Kérdések a feltételekről
- Forrás: NCT07134153: ki vehet részt
- A regiszteradat frissítve
- 2026. október 26.